Firat Uygur1, Hakan Tanrıverdi2, Murat Can3, Fatma Erboy2, Bulent Altınsoy2, Figen Atalay2, Tacettin Ornek2, Murat Damar4, Furuzan Kokturk5, Meltem Tor2. 1. Faculty of Medicine, Department of Pulmonary Medicine, Bulent Ecevit University, Kozlu/Zonguldak, 67600, Turkey. dr.fuygur@hotmail.com. 2. Faculty of Medicine, Department of Pulmonary Medicine, Bulent Ecevit University, Kozlu/Zonguldak, 67600, Turkey. 3. Faculty of Medicine, Department of Biochemistry, Bulent Ecevit University, Zonguldak, Turkey. 4. Faculty of Medicine, Department of Otolaryngology, Bulent Ecevit University, Zonguldak, Turkey. 5. Faculty of Medicine, Department of Biostatistics, Bulent Ecevit University, Zonguldak, Turkey.
Abstract
PURPOSE: Inflammation and oxidative stress play important roles in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). Omentin is expressed in visceral adipose tissue and is associated with the inflammatory response. The aim of this study was to assess the relationship between OSAS and omentin based on a comparison of its serum levels at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. METHODS: Ninety-six newly diagnosed OSAS patients and 31 non-apnoeic controls were enrolled in this study. Blood samples were obtained in the morning after polysomnography. Within the OSAS group, 30 patients were started on CPAP therapy and then reassessed clinically, including a blood test for serum omentin and other biochemical analysis, at 3 months. RESULTS: Serum omentin levels were significantly lower in the OSAS group than in the control group (27.7 ± 7.6 and 42.5 ± 5.2 ng/mL, P < 0.001). In the subgroup analysis, omentin concentrations were significantly lower in patients with severe OSAS than in those with mild/moderate OSAS (P < 0.001). Circulating omentin levels were significantly correlated with the apnoea-hypopnoea index (AHI), mean SaO2, oxygen desaturation index, and serum C-reactive protein levels. Treatment with CPAP resulted in a significant increase in circulating omentin levels after 3 months, from 22.7 ± 1.4 to 41.2 ± 3.3 ng/mL (P < 0.001). CONCLUSIONS: OSAS is associated with low serum omentin levels, and these levels can be reversed by effective CPAP treatment.
PURPOSE: Inflammation and oxidative stress play important roles in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). Omentin is expressed in visceral adipose tissue and is associated with the inflammatory response. The aim of this study was to assess the relationship between OSAS and omentin based on a comparison of its serum levels at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. METHODS: Ninety-six newly diagnosed OSAS patients and 31 non-apnoeic controls were enrolled in this study. Blood samples were obtained in the morning after polysomnography. Within the OSAS group, 30 patients were started on CPAP therapy and then reassessed clinically, including a blood test for serum omentin and other biochemical analysis, at 3 months. RESULTS: Serum omentin levels were significantly lower in the OSAS group than in the control group (27.7 ± 7.6 and 42.5 ± 5.2 ng/mL, P < 0.001). In the subgroup analysis, omentin concentrations were significantly lower in patients with severe OSAS than in those with mild/moderate OSAS (P < 0.001). Circulating omentin levels were significantly correlated with the apnoea-hypopnoea index (AHI), mean SaO2, oxygen desaturation index, and serum C-reactive protein levels. Treatment with CPAP resulted in a significant increase in circulating omentin levels after 3 months, from 22.7 ± 1.4 to 41.2 ± 3.3 ng/mL (P < 0.001). CONCLUSIONS: OSAS is associated with low serum omentin levels, and these levels can be reversed by effective CPAP treatment.
Authors: Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson Journal: Am J Respir Crit Care Med Date: 2002-07-15 Impact factor: 21.405
Authors: S Zirlik; K M Hildner; A Targosz; M F Neurath; F S Fuchs; T Brzozowski; P C Konturek Journal: J Physiol Pharmacol Date: 2013-06 Impact factor: 3.011
Authors: José María Moreno-Navarrete; Victoria Catalán; Francisco Ortega; Javier Gómez-Ambrosi; Wifredo Ricart; Gema Frühbeck; José Manuel Fernández-Real Journal: Nutr Metab (Lond) Date: 2010-04-09 Impact factor: 4.169